BioXcel Therapeutics (BTAI) PT Lowered to $13 at Goldman Sachs
Tweet
Share
E-mailGet Alerts BTAI Hot Sheet
Price: $1.19 +5.31%
Rating Summary:
7 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
7 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs analyst Corinne Jenkins lowered the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $13.00 (from $25.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- GMR Airports Infrastructure (GMRI:IN) PT Raised to INR99 at ICICI Securities
- Zedcor Inc (ZDC:CN) PT Raised to Cdn$7.75 at Desjardins
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
